SCHEMBL2397798

SCHEMBL2397798

CCn1c(CN2CCC(N3CC(F)C3)CC2)nc2c(N3CCOCC3)nc(Cl)nc21

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.43
HDAC1 Q13547 3/20 0.37
CYP3A4 P08684 2/20 0.36
PIK3CD O00329 5/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CA P42336 4/20 0.35
PIK3CG P48736 3/20 0.35
MTOR P42345 3/20 0.35
PDE10A Q9Y233 1/20 0.35
CNR2 P34972 2/20 0.35
PIK3R1 P27986 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396867 0.92 HRH3 (0.48) HRH3HDAC1CYP3A4PIK3CDPIK3CB
SCHEMBL2398167 0.90 HRH3 (0.46) HRH3HDAC1CYP3A4PIK3CDPIK3CB
SCHEMBL2394808 0.89 HRH3 (0.40) HRH3HDAC1CYP3A4PIK3CDPIK3CB
SCHEMBL2396327 0.87 HRH3 (0.43) HRH3HDAC1CYP3A4PIK3CDPIK3CB
SCHEMBL2398351 0.86 HRH3 (0.42) HRH3HDAC1CYP3A4PIK3CDPIK3CB
SCHEMBL12267966 0.86 TSHR (0.43) HRH3HDAC1CYP3A4PIK3CDPIK3CB
SCHEMBL2394691 0.85 HRH3 (0.42) HRH3HDAC1CYP3A4PIK3CDPIK3CA
SCHEMBL2396000 0.84 HRH3 (0.40) HRH3HDAC1CYP3A4PIK3CDPIK3CB
SCHEMBL2395837 0.83 PIK3CD (0.46) HDAC1CYP3A4PIK3CDPIK3CBPIK3CA
SCHEMBL2395688 0.83 CYP3A4 (0.37) HRH3HDAC1CYP3A4PIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2215090-B1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-03-04 EP disclosed
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 US disclosed
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 US disclosed
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS PIK3CA, PIK3CD, PI4KA HRH3 2781/4885HDAC1 3008/4885CYP3A4 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.